KNSA vs OMCL: fair value comparison
Kiniksa Pharmaceuticals International, plc and Omnicell, Inc. · Updated 2026-09-06
KNSA currently screens as fairly valued while OMCL screens as undervalued. Within Healthcare, OMCL currently sits closer to the top of our discount ranking.
| KNSA | OMCL | |
|---|---|---|
| Verdict | Fairly valued | Undervalued |
| Last price | $73.41 | $37.65 |
| 12-month range | $37.47–$73.41 | $29.96–$48.70 |
| Sector rank | #58 of 113 Healthcare | #54 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: KNSA fair value analysis · OMCL fair value analysis